Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy

Seung Yoon Park, In-San Kim

Research output: Contribution to journalShort survey

Abstract

Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.

Original languageEnglish
Pages (from-to)51-58
Number of pages8
JournalCancer letters
Volume452
DOIs
Publication statusPublished - 2019 Jun 28

Fingerprint

Myeloid Cells
Immunotherapy
Cytophagocytosis
Immunity
Neoplasms
Antigens
Tumor Microenvironment
Adaptive Immunity
Immunosuppressive Agents
Dendritic Cells
Macrophages
T-Lymphocytes

Keywords

  • Antitumer immunity
  • Dendritic cells
  • Macrophages
  • Phagocytosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. / Park, Seung Yoon; Kim, In-San.

In: Cancer letters, Vol. 452, 28.06.2019, p. 51-58.

Research output: Contribution to journalShort survey

@article{c023953e66fe42da80430bcd8ff1a7c8,
title = "Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy",
abstract = "Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.",
keywords = "Antitumer immunity, Dendritic cells, Macrophages, Phagocytosis",
author = "Park, {Seung Yoon} and In-San Kim",
year = "2019",
month = "6",
day = "28",
doi = "10.1016/j.canlet.2019.03.018",
language = "English",
volume = "452",
pages = "51--58",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy

AU - Park, Seung Yoon

AU - Kim, In-San

PY - 2019/6/28

Y1 - 2019/6/28

N2 - Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.

AB - Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity.

KW - Antitumer immunity

KW - Dendritic cells

KW - Macrophages

KW - Phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=85063328555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063328555&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2019.03.018

DO - 10.1016/j.canlet.2019.03.018

M3 - Short survey

VL - 452

SP - 51

EP - 58

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -